Grinchuk Oleg

Tumor-adjacent tissue co-expression profile analysis reveals pro-oncogenic ribosomal gene signature for prognosis of resectable hepatocellular carcinoma

Published date : 12 Dec 2017

Currently, molecular markers are not used when determining the prognosis and treatment strategy for patients with hepatocellular carcinoma (HCC). In the present study, we proposed that the identification of common pro-oncogenic pathways in primary tumors (PT) and adjacent non-malignant tissues (AT) typically used to predict HCC patient risks may result in HCC biomarker discovery. We examined the genome-wide mRNA expression profiles of paired PT and AT samples from 321 HCC patients.

type
Journal Paper
journal
Molecular Oncology, 8 Nov 2017, doi: 10.1002/1878-0261.12153
Impact Factor
5.314

Sense-antisense gene-pairs in breast cancer and associated pathological pathways

Published date : 28 Oct 2015

More than 30% of human protein-coding genes form hereditary complex genome architectures composed of sense-antisense (SA) gene pairs (SAGPs) transcribing their RNAs from both strands of a given locus. Such architectures represent important novel components of genome complexity contributing to gene expression deregulation in cancer cells. Therefore, the architectures might be involved in cancer pathways and, in turn, be used for novel drug targets discovery. However, the global roles of SAGPs in cancer pathways has not been studied.

type
Journal Paper
journal
Oncotarget. 2015 Dec 8;6(39):42197-221. doi: 10.18632/oncotarget.6255
Impact Factor
6.359

Genome and transcriptome delineation of two major oncogenic pathways governing invasive ductal breast cancer development

Published date : 10 Oct 2015

Invasive ductal carcinoma (IDC) is a major histo-morphologic type of breast cancer. Histological grading (HG) of IDC is widely adopted by oncologists as a prognostic factor. However, HG evaluation is highly subjective with only 50%–85% inter-observer agreements. Specifically, the subjectivity in the assignment of the intermediate grade (histologic grade 2, HG2) breast cancers (comprising ~50% of IDC cases) results in uncertain disease outcome prediction and sub-optimal systemic therapy.

type
Journal Paper
journal
Oncotarget 2015, DOI: 10.18632/oncotarget.5543
Impact Factor
6.359